Short Interest in Kamada Ltd. (NASDAQ:KMDA) Increases By 19.6%

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 85,924 shares, an increase of 19.6% from the December 31st total of 71,840 shares. Based on an average trading volume of 88,172 shares, the short-interest ratio is presently 1.0 days. Currently, 0.2% of the company’s shares are short sold. Currently, 0.2% of the company’s shares are short sold. Based on an average trading volume of 88,172 shares, the short-interest ratio is presently 1.0 days.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research note on Thursday, January 8th. Wall Street Zen upgraded Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. HC Wainwright lifted their price objective on shares of Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

Hedge Funds Weigh In On Kamada

A number of institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kamada during the fourth quarter valued at approximately $66,000. Simplicity Wealth LLC purchased a new position in Kamada during the 3rd quarter worth $70,000. Jump Financial LLC purchased a new position in Kamada during the 2nd quarter worth $219,000. Man Group plc bought a new stake in Kamada during the 3rd quarter valued at $199,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Kamada in the 1st quarter worth $206,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Stock Performance

Kamada stock traded down $0.09 during mid-day trading on Wednesday, hitting $8.10. The company’s stock had a trading volume of 108,307 shares, compared to its average volume of 82,137. The company has a 50 day moving average of $7.48 and a 200-day moving average of $7.19. Kamada has a one year low of $5.54 and a one year high of $9.15. The stock has a market cap of $465.83 million, a PE ratio of 22.50, a P/E/G ratio of 0.70 and a beta of 0.94.

Kamada (NASDAQ:KMDA) last released its earnings results on Monday, November 10th. The biotechnology company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). The business had revenue of $47.01 million for the quarter, compared to the consensus estimate of $154.21 million. Kamada had a return on equity of 7.89% and a net margin of 11.70%. On average, equities research analysts forecast that Kamada will post 0.23 EPS for the current fiscal year.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.